Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review
Metadatos
Mostrar el registro completo del ítemAutor
Perazzoli, Gloria; Peña Contreras, María Mercedes; Prados Salazar, José Carlos; Melguizo Alonso, Consolación; Jiménez Luna, CristinaEditorial
MDPI
Materia
Pancreatic cancer Metabolomics Biomarkers Early diagnosis Systematic Review
Fecha
2023-07-22Referencia bibliográfica
Perazzoli, G.; García-Valdeavero, O.M.; Peña, M.; Prados, J.; Melguizo, C.; Jiménez-Luna, C. Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review. Metabolites 2023, 13, 872. [https://doi.org/10.3390/metabo13070872]
Patrocinador
B-TIC-414-UGR18 (Junta deAndalucía 2020) (FEDER)Resumen
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with five-year
survival rates around 10%. The only curative option remains complete surgical resection, but due
to the delay in diagnosis, less than 20% of patients are eligible for surgery. Therefore, discovering
diagnostic biomarkers for early detection is crucial for improving clinical outcomes. Metabolomics
has become a powerful technology for biomarker discovery, and several metabolomic-based panels
have been proposed for PDAC diagnosis, but these advances have not yet been translated into the
clinic. Therefore, this review focused on summarizing metabolites identified for the early diagnosis
of PDAC in the last five years. Bibliographic searches were performed in the PubMed, Scopus and
WOS databases, using the terms “Biomarkers, Tumor”, “Pancreatic Neoplasms”, “Early Diagnosis”,
“Metabolomics” and “Lipidome” (January 2018–March 2023), and resulted in the selection of fourteen
original studies that compared PDAC patients with subjects with other pancreatic diseases. These
investigations showed amino acid and lipid metabolic pathways as the most commonly altered,
reflecting their potential for biomarker research. Furthermore, other relevant metabolites such as
glucose and lactate were detected in the pancreas tissue and body fluids from PDAC patients. Our
results suggest that the use of metabolomics remains a robust approach to improve the early diagnosis
of PDAC. However, these studies showed heterogeneity with respect to the metabolomics techniques
used and further studies will be needed to validate the clinical utility of these biomarkers